Sun Ophthalmics Looks to Build a Brand-New Business in the US

04/28/16 • 19 min

OIS Podcast | Ophthalmology's leading Podcast

Sun Pharma, the fifth largest pharma company in the US, targeted ophthalmology as one of the first planks in its new branded pharma business. Hear ophthalmology veteran Jerry St. Peter explain how Sun Ophthalmics hopes to build a new team in ophthalmology.

Previous Episode

Avedro’s Long Wait for FDA Approval is Over

The FDA approved Avedro’s New Drug Application for its riboflavin ophthalmic solution/KXL System (corneal cross-linking for the treatment of keratoconus and corneal ectasia following refractive surgery). OIS Co-chair Gil Kliman, an investor in Avedro, lays out the company’s next plans.

Next Episode

Graybug Vision – Flush with Cash – Is Making Big Moves to Change its Approach to Finding New Treatments for Wet AMD & Other Eye Disease

Graybug interim CEO Jeff Cleland shares details on the company’s $44.5 million Series B. Cleland gives a report on investor appetite for ophthalmology companies. He also explains how the firm would use the capital to shift its approach from a drug delivery platform technology company to a drug maker.